DESCAR-T is the common registry for all CAR-T treatments for the pharmaceutical companies that produce them. The purpose of this registry is to support data on the short and long-term efficacy and safety of these treatments.
RoActemra® (Tocilizumab) is developed and commercialized by the pharmaceutical companies Roche et Chugai. It has an indication in the treatment of severe Cytokine Release Syndromes (CRS) that may be induced by CAR-T.
The pharmaceutical company Chugai Pharma France* has contacted the LYSARC to evaluate the safety and efficacy of RoActemra® in the treatment of SRC associated with CAR-T treatment, based on data from the DESCAR-T registry. This request meets the Registry’s research purpose on lymphoma and serves a public interest purpose. The analysis will be conducted on the data of patients treated with CAR T-cells, who have received tocilizumab, whose data are available in the registry.
The LYSARC will perform the analysis and send only descriptive reports to the company, where results are anonymised (i.e. there is no possibility to identify a patient from the information in the report). There is no transfer of individual data to the laboratory.
To patients in the DESCAR-T registry, if you would like more information about the processing of your data in the DESCAR-T Registry, you can contact the doctor at your care center for your CAR-T treatment or make a request at dpo@lysarc.org. You can also find more details your rights regarding your personal data in the homepage, in the section “I am participating or have participated in a clinical trial“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.
*Chugai Pharma France laboratory is located Tour Franklin – Arche Sud, 100/101 Quartier Boieldieu, 92042 Paris La Défense.